ECOLAB INC.

Lobbying for ECOLAB INC

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Expenses

$420,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 10

Commerce, Dept of (DOC)
Energy, Dept of
Environmental Protection Agency (EPA)
Executive Office of the President (EOP)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Interior, Dept of (DOI)
SENATE
State, Dept of (DOS)

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 1

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 5

Environment/Superfund

Discussions related to environmental policies and issues including water infrastructure, water reuse, water efficiency, water resource management, and sustainability. Discussions related to energy and water efficiency initiatives. Discussions related to the implementation of the Pesticide Registration Improvement Act, P.L.117-103. Discussions related to data center water efficiency and energy efficiency.

Taxation/Internal Revenue Code

Discussions regarding scope of Sec. 48D investment tax credit; Discussions related to corporate taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Trade (domestic/foreign)

Discussions related to supply chain challenges. Discussions regarding trade policy and tariffs.

Energy/Nuclear

Discussions regarding sustainable aviation fuel. Discussions regarding permitting reform. Discussions regarding Department of Energy programs for critical mineral production, including the use of resins as extraction technology. Discussions regarding optimization of power generation.

Pharmacy

Discussions regarding biopharmaceutical manufacturing policy. Discussions regarding animal health.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.